Not independent
Tenure on this board
10.2 yrs
Also a director at
Citius Oncology Inc (CTOR)
7 nominees · 2 ballot items.
Elect seven directors to serve until the 2027 Annual Meeting and ratify Wolf & Company, P.C. as the Company’s independent auditor for the fiscal year ending September 30, 2026.
Elect seven directors to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
Ratify the Board’s selection of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 0.8% | 208,926 | $188K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 0.6% | 167,738 | $151K |
| 3 | VANGUARD FIDUCIARY TRUST CO | 0.3% | 77,755 | $70K |
| 4 | BlackRock, Inc. | 0.3% | 69,851 | $63K |
| 5 | HRT FINANCIAL LP | 0.2% | 60,332 | $54K |
| 6 | Asset Advisory Group, Inc. | 0.2% | 59,011 | $53K |
| 7 | NORTHERN TRUST CORP | 0.2% | 43,974 | $40K |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.1% | 37,232 | $34K |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.1% | 36,838 | $33K |
| 10 | UBS Group AG | 0.1% | 28,099 | $25K |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.